. 2022 Jun 18;65:32–40. doi: 10.1016/j.breast.2022.06.003

Table 3.

Representative cancers associated with truncating BARD1 and RAD51D variants.

	Life-time risk in general population	Life-time risk in BARD1 Carriers	BARD1 truncating variants	Case series/case control studies with BARD1	Life-time risk in RAD51D Carriers	Case series/case control studies RAD51D
BC	12.4%	>20%	X	10901 TNBC [69]	15–40%	10901 TNBC [69]
TNBC	12.4%	>20%	X	10901 TNBC [69]	x	10901 TNBC [69]
OC	1.2%	Not established	Not established	Not established	10–15%	911 cases (BC/OC families) vs 1060 controls [72]
Neuroblastoma	Not well defined in childhood population	Not established	X*	−397 high risk neuroblastoma vs 2043 controls [70]	–	–

*Preliminary data.